Immunogenicity of Pfizer mRNA COVID-19 Vaccination Followed by J&J Adenovirus COVID-19 Vaccination in Two Patients with Chronic Lymphocytic Leukemia

Figure 1

Immune response to COVID-19 vaccination in CLL subjects. RBD-specific antibody titer. Subjects without a detectable antibody titer (<1 : 50 serum dilution) were assigned a value of 49. The limit of detection (LOD) is 50. Frequency of RBD-specific MBCs per 10⁶ CD19+ B-cells following ex vivo stimulation. Subjects who did not have a detectable response were assigned a value between 0.07 and 0.09. The limit of detection (LOD) is 0.1. SARS-CoV-2 spike peptide-reactive CD4 and CD8 T-cells are defined as double positive for IFNγ and TNFα cytokine secretion. Patients who did not have a detectable T-cell response were assigned an arbitrary number less than 2. The limit of detection (LOD) is 10. Visit 1 (pre) blood draw was taken 21 and 40 days prior to the Pfizer vaccine series (2-doses). Visit 2 (V2) blood draw was taken 33 and 24 days post vaccination, and Visit 3 (V3) was drawn 30 and 27 days after the 3rd vaccination with J&J.